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Copyright © 2005 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.03.029Arecent editorial, the first on this subject, appeared in the Journal1: “ToSTICH or not to STICH: We know the answer, but do we understand thequestion?” Although the article indicates the answer is “to STICH,” this
report asks whether the STICH investigators’ response understood the question.
Patient Selection and Inclusion Criteria
The underlying principle of the STICH (Surgical Treatment for IschemiC Heart
failure) trial involves recognition of the potentially lethal complications of enlarging
ventricular volume, and its questions are closely linked to volume measurements,
the first entry criteria for inclusion in the trial. This fundamental concept stems from
the seminal work of White and colleagues,2 showing how increased left ventricular
end-systolic volume affects mortality. For example, Figure 1A shows that doubling
of mortality follows doubling of volume and defines how death rate worsens after
the progressive end-systolic volume expansion. Measuring ventricular volume is a
central ingredient of the STICH trial and is expressed as left ventricular end-systolic
volume index (LVESVI) in the database. The congestive heart failure (CHF)
community must recognize that this vital measurement reflects a major departure
from conventional analysis because ejection fraction is now the traditional marker.
White and colleagues2 have shown, in Figure 1B, the survival discrepancy between
conventional ejection fraction and LVESVI measurement. Unfortunately, this cen-
tral issue is never raised in the invited editorial that just appeared in the Journal.
The normal LVESVI is less than 30 mL/m2, and STICH trial participants are
separated into groups, depending on whether LVESVI is less than 60 mL/m2
(medical therapy and coronary artery bypass grafting [CABG]) or greater than 60
mL/m2, where surgical ventricular restoration (SVR) is also tested. Senior, Lahiri,
and Kaul3 published a nonrandomized report in which the entry criterion was
LVESVI of approximately 60 mL/m2 and compared medical therapy and CABG.
Follow-up data (Figure 2) demonstrated that prognosis was determined on the basis
of LVESVI changes over 4 years and was independent of the treatment category.
The STICH trial will place randomization into this equation.
A second inclusion criterion is measuring the asynergic (noncontracting region)
area: this nonfunctional segment (if it exceeds 35% of the left ventricular [LV]
perimeter) reflects the ischemic region scar that triggers compensating remote
muscle dilation. Another inclusion criterion involves demonstration that the asyn-
ergic region is limited to one of the 3 major segments. This concept is based on
recognition that revascularization (CABG) of viable remote muscle in nonscarred
segments might improve compensatory contractile recovery after the scar is either
grafted (in small hearts) or excluded after SVR in larger ventricles. The “remote area
concept” reflects an important reason for viability determination of nonscarred
regions supplied by the circumflex and right coronary vessels, as was done in the
case report.
Consequently, the surgeon and cardiologist must ask 3 different questions than
those posed by the authors of this article: (1) How much asynergy (ie, the scar nidus
of dilation) exists; (2) is there sufficient compensatory muscle (seen by means of
magnetic resonance imaging [MRI], ventriculography, echocardiography, and nu-
clear medicine studies of remote regions) to resume function; and (3) what is the
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MRI, biplane ventriculography, nuclear medicine, and
echocardiography?
It seems that a very important task of this prior editorial
is to advise the cardiologist or surgeon who wonders how to
treat such a patient that the enclosed workup does not
provide the STICH team with sufficient information to
answer the basic questions that underlie this trial. Failure to
address these issues during a response to individuals posing
this STICH trial question suggests that the authors do not
(1) use these basic criteria in their selection or (2) advise
inquiring physicians that correct use of these inclusion
criteria is essential to understand this trial.
246 The Journal of Thoracic and Cardiovascular Surgery ● AuguThe STICH protocol uses LVESVI measurement to
make decisions about placing patients into the 3 study
groups. If volume is less than 60 mL/m2, the intervention
decision relates to comparing the effects of either using
medical treatment or adding CABG. Recruitment is down in
this 1600-patient cohort because cardiologists are aware that
all trials and registries show the benefit of CABG in im-
proving survival in ischemic patients, as summarized in
their reported Coronary Artery Surgery Study, and simply
do not wish to withhold revascularization in patients with
ischemic CHF. More importantly, the editorial does not
define limitations of the 3-year observation period, does not
Figure 1. A, Relationship between LV end-
systolic volume and mortality. Note that
(1) volume is in milliliters, not milliliters
per square meter, so that the LVESVI
would be twice this number if patient size
is 2 m and (2) that volume increase is a
surrogate for increased mortality. (Re-
printed with permission from White HD,
Norris RM, Brown MA, Brandt PW, Whit-
lock RM, Wild CJ. Left Ventricular End-
Systolic Volume as the Major Determinant
of Survival After Recovery From Myocar-
dial Infarction. Circulation. 1987;76[1]:44-
51.) B, Comparison of prognosis in survi-
vors and nonsurvivors in relationship to
ejection fraction (solid line is at 35%) and
LV end-systolic volume in milliliters. Note
that lower LV end-systolic volume at 35%
ejection fraction is associated with re-
duced mortality in survivors compared
with increased mortality in nonsurvivors
when LV end-systolic volume is higher at
35% ejection fraction. (Reprinted with per-
mission from White HD, Norris RM, Brown
MA, Brandt PW, Whitlock RM, Wild CJ.
Left Ventricular End-Systolic Volume as
the Major Determinant of Survival After
Recovery From Myocardial Infarction. Cir-
culation. 1987;76[1]:44-51.)emphasize the downward survival trajectory observed with
st 2005
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database showing the advantages of CABG versus medical
treatment over a 10-year follow-up interval.6 Of interest,
this Duke database did not include recurrent CHF as a late
problem7 because they only followed death, new myocar-
dial infarction, or repeat CABG as adverse follow-up
events.
If volume is greater than 60 mL/m2, a frequent finding in
patients with CHF, the decision question relates to how
SVR fits into the treatment scheme in 1200 patients. A first
cohort is divided into 600 patients who do not have either
angina or critical coronary lesions and are treated with
medical therapy, CABG, or CABG and SVR. The second
cohort involves a 600-patient subgroup with angina or crit-
ical lesions that will undergo CABG with or without SVR.
There is no problem in recruitment in this last group.
Viability and Revascularization
The issue of viability is somewhat confusing in this editorial
because an inclusion criterion for STICH consideration is
infarction of the anterior septal region. Consequently, ob-
servation of anterior viability in the STICH trial is not as
vital in the asynergic scar (the size of which must be
measured as 35% of LV perimeter on right anterior
oblique ventriculography) as determination of viability of
remote muscle that might develop compensatory improve-
Figure 2. Four-year prognosis of patients treated with either
medical therapy or CABG, with an entry criteria of LVESVI ap-
proximately 60 mL/m2. Note the improved prognosis if LVESVI did
not change and downward mortality trajectory as LVESVI in-
creased. *Medical or CABG therapy. (Reprinted from The Amer-
ican Journal of Cardiology, vol 88, Senior R, Lahiri A, Kaul S,
Effect of Revascularization on Left Ventricular Remodeling in
Patients With Heart Failure From Severe Chronic Ischemic Left
Ventricular Dysfunction, p 624-9. Copyright © 2001, with permis-
sion from Excerpta Medica, Inc.)ment after revascularization. This remote muscle is viable in
The Journal of Thoracithe patient presented in the editorial. However, the respon-
sibility of the authors is to clarify the trial focus by empha-
sizing that the surgeon and cardiologist must look at the
compensating muscle8 rather than the scar, which currently
remains the focal area of interest during current viability
testing. Addressing remote muscle should be an important
Figure 3. A, Relationship of ejection fraction (EF) and LVESVI in a
cohort of patients with CHF. Note that at an ejection fraction of
35%, LVESVI can range between less than 60 to greater than 120
mL/m2. (Reprinted from Buckberg GD, Congestive Heart Failure:
Treat the Disease, not the Symptom—Return to Normalcy. J Tho-
rac Cardiovasc Surg. 2001;121:628-37.) B, Comparison of 60-month
mortality against cumulative survival (hospital deaths excluded)
for LVESVI. Note increased mortality as preoperative LVESVI is
increased. (From Di Donato M, Toso A, Maioli M, Sabatier M,
Stanley AW Jr, Dor V, et al. Intermediate Survival and Predictors
of Death After Surgical Ventricular Restoration. Semin Thorac
Cardiovasc Surg. 2001;13:468-75. Reprinted with permission of
W. B. Saunders Company.)component of this editorial because such leadership will
c and Cardiovascular Surgery ● Volume 130, Number 2 247
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the decision tree that underlies the STICH trial.
Additionally, discussions about the importance of viabil-
ity studies while making decisions about the role of surgical
revascularization should overview the recent work of Mahr-
holdt and associates.9 Their findings emphasize the gado-
linium aspect of MRI scans (MRI is a part of the STICH
trial) by analyzing the amount of damage within the infarct
area scar. This is a critical aspect of the evaluation process
because most patients show an akinetic rather than a dys-
kinetic scar. This wall motion finding relates to the conse-
quences of reperfusion by thrombolysis or percutaneous
transluminal coronary angioplasty, which salvages the epi-
cardial (and potentially mid myocardial) surface of the
infarct region. Early reflow will prevent transmural bulging
(dyskinesia) and creates the akinetic area that differs from
the aneurysm previously treated by Cooley and cowork-
ers,10 when reperfusion strategies were not used. The au-
thors should use this new MRI information to explain why
successful revascularization will not allow contractile re-
covery if more than 50% of muscle is scarred by gadolin-
ium.9 They should also point out that the critical issue is not
viability of the scar but rather recognition of why segmental
contraction of the scar cannot improve through revascular-
ization of regions containing extensive nonviable muscle.
The SVR procedure understands this logic because the
operation excludes this nonfunctional region.
Surgical Ventricular Restoration for Ischemic Heart
Failure
The authors present a limited overview of the background
role of SVR to treat the dilated heart. Aside from excluding
the vital importance of volume measurements,2 they should
focus on past reports that clarify why bigger ventricular
volumes might limit prognosis.11,12 Di Donato and cowork-
ers8,12 reported longitudinal survival studies that demon-
strate better survival and functional outcome after SVR
interventions when LVESVI is not markedly increased.
Athanasuleas and associates13-15 found similar late findings,
especially in the recent 5-year follow-up of 1198 patients
undergoing SVR in the recent RESTORE* team report. The
critical role of volume must be clarified because the authors
introduce a CABG article that uses ejection fraction rather
than volume measurements to quantify recovery as a con-
trast to SVR findings of the RESTORE group.16
Luciani and coworkers7 provided evidence of the prog-
nostic importance of volume rather than ejection fraction, in
which a 7-year CABG patient study follow-up identified
differences between improved ejection fraction (in his pa-
tients) and observed progressive increase of ventricular vol-
ume and CHF worsening. These adverse clinical events*Reconstructive Endoventricular Surgery, returning Torsion Original Radius
Elliptical Shape.
248 The Journal of Thoracic and Cardiovascular Surgery ● Auguexisted despite improved survival after CABG therapy, and
the authors stress the importance of measuring ventricular
volume and body oxygen uptake to assess recovery. Fur-
thermore, Di Donato and coworkers12 (Figure 3) have con-
firmed the data of White and associates2 by showing that
volume, rather than ejection fraction, is the vital prognostic
component. Yamaguchi and colleagues17 have also empha-
sized the prognostic importance of LVESVI by showing
impaired prognosis and increasing incidence of CHF when
preoperative LVESVI is greater than 100 mL/m2. This 1998
observation is now updated17,18 by a 2005 report showing
that the 54% mortality that followed successful CABG in a
patient population whose preoperative LVESVI value was
greater than 100 mL/m2 was improved to 90% 5-year sur-
vival after restoration (SVR) to produce LV rebuilding.
Evidence-Based Medicine and Experience
Evidence-based medicine is the recurrent theme in survey-
ing randomized series. The validity of surgical trials pow-
ered to yield creditable results must also address 2 other
components: technical proficiency and competent myocar-
dial protection. The importance of adding this credibility
concept to surgical trial design was clear from a 1977
Veterans Affairs’ randomized CABG study that was done in
597 patients that included 286 surgical and 310 medical
patients.19 The authors reported 5.6% surgical mortality,
with postoperative deaths ranging from 2% to 12%, a result
that was closely linked to an experience within 12 partici-
pating individual centers19 that showed similar 36 month
outcomes. In 1978, the Cleveland Clinic reported a nonran-
domized series of 1000 patients with a mortality of less than
1%.20 The overall clinical effect favored experience because
obstructed vessels are now treated with revascularization,
and current dialogue only relates to creation of the open
vessel by using either angioplasty or surgical approaches.
The STICH trial might fall into a similar category be-
cause 2800 patients will be studied within the many US and
international centers. The editorial states that there is not
general acceptance of the SVR procedure that will be per-
formed in only 500 patients among more than 90 partici-
pating STICH centers. The potential of approximately 5
patients per center suggests that ensuring competence is
essential during evaluation of the role of SVR in high-risk
patients with CHF. The recent RESTORE report in 1198
patients (from only 11 contributing centers) might provide
some guidelines by reporting 5.3% operative mortality:
4% after SVR and CABG and 8.7% if mitral repair or
replacement are added in very large ventricles. This recent
RESTORE database might set a benchmark for in-hospital
mortality to be expected from STICH centers. Statisticians
accurately establish evidence-based medicine, but input for
their trial database must involve a safe level of technical
competence and satisfactory myocardial protection, so that
st 2005
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surgical method.
Conclusions
The questions asked by this current editorial suggest that the
editorial of STICH investigators should have advised the
cardiologist or surgeon who asks the question “How would
you treat this patient?” that the initial workup summary did
not have the right measurements. Information on asynergy,
remote muscle, and volume are central factors in the STICH
evaluation. An important message involves clarifying that
the referring physician must know that ejection fraction is a
less helpful number than LVESV and suggesting how to
obtain this key measurement.
Furthermore, advice about the viability of remote muscle
is a new theme and should be emphasized. Additionally,
they should define ways that MRI allows study of the
underlying scar of the akinetic heart to improve understand-
ing of why its grafting or exclusion might affect prognosis,
especially in the 1200 patients with CHF who become SVR
candidates. Identifying limitations of 3-year follow-up is
needed because medical therapy options are vastly im-
proved. Recognizing this limitation naturally leads to em-
phasizing the importance of long-term follow-up intervals
that are a critical STICH trial component, especially be-
cause 10-year data about CABG in the Coronary Artery
Surgery Study are discussed. Finally, focus on the role of
experience during any randomized surgical series is impor-
tant to avoid unbiased results. Surgeons act and statisticians
count, and both must be done well to define how any
randomized or nonrandomized trial can affect future
actions.
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